Your browser doesn't support javascript.
loading
Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction.
Santema, Bernadet T; Kloosterman, Mariëlle; Van Gelder, Isabelle C; Mordi, Ify; Lang, Chim C; Lam, Carolyn S P; Anker, Stefan D; Cleland, John G; Dickstein, Kenneth; Filippatos, Gerasimos; Van der Harst, Pim; Hillege, Hans L; Ter Maaten, Jozine M; Metra, Marco; Ng, Leong L; Ponikowski, Piotr; Samani, Nilesh J; Van Veldhuisen, Dirk J; Zwinderman, Aeilko H; Zannad, Faiez; Damman, Kevin; Van der Meer, Peter; Rienstra, Michiel; Voors, Adriaan A.
Afiliação
  • Santema BT; Department of Cardiology, University of Groningen, Hanzeplein 1, GZ, Groningen, the Netherlands.
  • Kloosterman M; Department of Cardiology, University of Groningen, Hanzeplein 1, GZ, Groningen, the Netherlands.
  • Van Gelder IC; Department of Cardiology, University of Groningen, Hanzeplein 1, GZ, Groningen, the Netherlands.
  • Mordi I; School of Medicine Centre for Cardiovascular and Lung Biology, Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK.
  • Lang CC; School of Medicine Centre for Cardiovascular and Lung Biology, Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK.
  • Lam CSP; Department of Cardiology, University of Groningen, Hanzeplein 1, GZ, Groningen, the Netherlands.
  • Anker SD; National Heart Centre Singapore, Hospital Drive, Singapore.
  • Cleland JG; Division of Cardiology and Metabolism-Heart Failure, Cachexia & Sarcopenia; Department of Cardiology (CVK), Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité University Medicine, Charitépl. 1, Berlin, Germany.
  • Dickstein K; National Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College, Sydney St, Chelsea, London, UK.
  • Filippatos G; Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, University Avenue, Glasgow, UK.
  • Van der Harst P; University of Bergen, Bergen, Norway.
  • Hillege HL; Stavanger University Hospital, Gerd-Ragna Bloch Thorsens Gate 8, Stavanger, Norway.
  • Ter Maaten JM; National and Kapodistrian University of Athens, School of Medicine & Department of Cardiology, Heart Failure Unit, Athens University Hospital Attikon, 1, Rimini Str, Haidari, 124 62 Athens, Greece.
  • Metra M; Department of Cardiology, University of Groningen, Hanzeplein 1, GZ, Groningen, the Netherlands.
  • Ng LL; School of Medicine Centre for Cardiovascular and Lung Biology, Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK.
  • Ponikowski P; Department of Cardiology, University of Groningen, Hanzeplein 1, GZ, Groningen, the Netherlands.
  • Samani NJ; Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Piazza del Mercato, 15, Brescia, Italy.
  • Van Veldhuisen DJ; Department of Cardiovascular Sciences, University of Leicester, Groby Road, Leicester, UK.
  • Zwinderman AH; NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Groby Road Leicester, UK.
  • Zannad F; Department of Heart Diseases, Wroclaw Medical University, Rudolfa Weigla 5, 53-114 Wroclaw, Poland.
  • Damman K; Cardiology Department, 4th Military Hospital, Rudolfa Weigla, 50-981 Wroclaw, Poland.
  • Van der Meer P; Department of Cardiovascular Sciences, University of Leicester, Groby Road, Leicester, UK.
  • Rienstra M; NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Groby Road Leicester, UK.
  • Voors AA; Department of Cardiology, University of Groningen, Hanzeplein 1, GZ, Groningen, the Netherlands.
Eur Heart J ; 39(43): 3867-3875, 2018 11 14.
Article em En | MEDLINE | ID: mdl-30137304
Aims: The clinical correlates and consequences of atrial fibrillation (AF) might be different between heart failure with reduced vs. preserved ejection fraction (HFrEF vs. HFpEF). Biomarkers may provide insights into underlying pathophysiological mechanisms of AF in these different heart failure (HF) phenotypes. Methods and results: We performed a retrospective analysis of the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF), which was an observational cohort. We studied 2152 patients with HFrEF [ejection fraction (EF < 40%)], of which 1419 were in sinus rhythm (SR) and 733 had AF. Another 524 patients with HFpEF (EF ≥50%) were studied, of which 286 in SR and 238 with AF. For the comparison of biomarker profiles, 92 cardiovascular risk markers were measured (Proseek® Olink Cardiovascular III panel). The circulating risk marker pattern observed in HFrEF was different than the pattern in HFpEF: in HFrEF, AF was associated with higher levels of 77 of 92 (84%) risk markers compared to SR; whereas in HFpEF, many more markers were higher in SR than in AF. Over a median follow-up of 21 months, AF was associated with increased mortality risk [multivariable hazard ratio (HR) of 1.27; 95% confidence interval (CI) 1.09-1.48, P = 0.002]; there was no significant interaction between heart rhythm and EF group on outcome. Conclusion: In patients with HFrEF, the presence of AF was associated with a homogeneously elevated cardiovascular risk marker profile. In contrast, in patients with HFpEF, the presence of AF was associated with a more scattered risk marker profile, suggesting differences in underlying pathophysiological mechanisms of AF in these HF phenotypes.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Volume Sistólico / Insuficiência Cardíaca Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Volume Sistólico / Insuficiência Cardíaca Idioma: En Ano de publicação: 2018 Tipo de documento: Article